Verastem Oncology is debuting a digital campaign to help people understand the differences in low-grade serous ovarian cancer.

Ve­rastem's new cam­paign aims to make dis­tinc­tions in rare type of ovar­i­an can­cer

When Tiffany Stout was first di­ag­nosed with ovar­i­an can­cer in 2015, she didn’t im­me­di­ate­ly take in the fact that it was specif­i­cal­ly the low-grade serous type. It wasn’t un­til she met with her doc­tor lat­er and un­der­stood she had low-grade serous ovar­i­an can­cer (LGSOC), a rare dis­ease that grows more slow­ly than the more com­mon high-grade serous type, but that is al­so re­sis­tant to chemother­a­py and high­ly re­cur­rent.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.